Safety and Targeting of Anti-hk2 Antibody in mCRPC

Inclusion Criteria: * Subjects with mCRPC will be eligible if they meet the following criteria: * Eastern Cooperative Oncology Group (ECOG) ≤ 1 * Histologically or cytologically confirmed adenocarcinoma of the prostate * Castrate levels of testosterone (\<50 ng/dL \[1.74 nmol/L\]) * Metastatic disease documented by imaging * Documented progressive mCRPC with androgen involvement as defined by - Prostate Cancer Working Group 3 * Acceptable laboratory parameters * At least 28 days since administration of any therapeutic radioactive isotope * Able to tolerate the conditions required to perform imaging studies (e.g., lying flat for at least 1 hour). Exclusion Criteria: * Known hypersensitivity to proteins, or other allergic diathesis that, in the opinion of the investigator, makes an immune response to humanized antibody likely * Radiotherapy or immunotherapy within 30 days, or single fraction of palliative radiotherapy within 14 days of administration of study agent * Any condition that, in the opinion of the Investigator, would impair the subject's ability to comply with study procedures and required study visits * Active, symptomatic, or untreated brain metastases.